soft tissue sarcoma


Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.

soft tissue sarcoma

Oncology A sarcoma that arises in muscle, fat, fibrous tissue, blood vessels, or other supporting tissues. See Sarcoma.
Soft tissue sarcoma staging
I A Tumor cells are morphologically similar to normal cells; tumor measures ≤ 5 cm
 B Ditto; tumor ≥ 5 cm
II A Tumor cells are mildly atypical; tumor measures ≤ 5 cm
 B Ditto; tumor ≥ 5 cm
III A Tumor cells are moderately or severely atypical/bizarre; tumor measures ≤ 5 cm
 B Ditto; tumor ≥ 5 cm
IV A Any cellular atypia; any sized tumor with lymph node involvement
 B Any cellular atypia; any sized tumor with metastasis  
References in periodicals archive ?
Soft tissue sarcomas of childhood and adolescence: the prognostic role of tumor size in relation to patient body size.
Combined surgery and radiation therapy for limb preservation in soft tissue sarcoma of the extremity: the Massachusetts General Hospital experience.
While soft tissue sarcomas are relatively rare, there remains an unmet medical need for patients who often fail to respond to treatment and therefore have a poor prognosis.
Leiomyosarcoma is the third most common soft tissue sarcoma.
Identification of soft tissue sarcoma deaths in cohorts exposed to dioxin and to chlorinated naphthalenes.
Reproducibility of a histopathologic grading system for adult soft tissue sarcoma.
Company is planning to submit a special protocol assessment to the FDA related to its Phase 3 pivotal trial with aldoxorubicin for patients with advanced soft tissue sarcomas
Study 309 is a randomised, open-label multicentre Phase III study comparing the efficacy and safety of eribulin vs dacarbazine in adults with one of two soft tissue sarcoma subtypes (adipocytic sarcoma or leiomyosarcoma) previously treated with an anthracycline and at least two prior regimens after anthracycline failure.
A phase III trial of palifosfamide in first line soft tissue sarcoma (PICASSO III) is underway with progression-free survival results expected later this year.
Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for eribulin mesylate (eribulin) being evaluated for patients with inoperable soft tissue sarcoma (leiomyosarcoma and liposarcoma) who have received prior chemotherapy for advanced or metastatic disease.
Treatment was administered on days one and eight of a 21-day cycle versus dacarbazine to patients with one of two subtypes: adipocytic or leiomyosarcoma locally advanced or relapsed and metastatic soft tissue sarcoma who showed disease progression following standard therapies which must have included an anthracycline and at least one other additional regimen.
A phase III trial in soft tissue sarcoma is also underway with an interim survival analysis expected by year-end 2013.